middle.news
Syntara Advances Clinical Pipeline with FDA Support and $8.8M Capital Raise
2:49pm on Thursday 27th of August, 2026 AEST
•
Healthcare
Read Story
Syntara Advances Clinical Pipeline with FDA Support and $8.8M Capital Raise
2:49pm on Thursday 27th of August, 2026 AEST
Key Points
Revenues down 7.9% to $7.03 million
Net loss after tax rises 13.6% to $9.0 million
FDA supports Phase 2b trial design for amsulostat
Expanded clinical programs in blood cancers and pancreatic cancer
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE